[go: up one dir, main page]

ATE140388T1 - Zusammensetzungen enthaltend omega conotoxin peptide derivate und deren verwendung zur behandlung von ischämie-artigen neuronalen schädigungen - Google Patents

Zusammensetzungen enthaltend omega conotoxin peptide derivate und deren verwendung zur behandlung von ischämie-artigen neuronalen schädigungen

Info

Publication number
ATE140388T1
ATE140388T1 AT91901056T AT91901056T ATE140388T1 AT E140388 T1 ATE140388 T1 AT E140388T1 AT 91901056 T AT91901056 T AT 91901056T AT 91901056 T AT91901056 T AT 91901056T AT E140388 T1 ATE140388 T1 AT E140388T1
Authority
AT
Austria
Prior art keywords
ischemia
treatment
compositions containing
conotoxin peptide
peptide derivatives
Prior art date
Application number
AT91901056T
Other languages
English (en)
Inventor
George P Miljanich
Robert S Bitner
Stephen S Bowersox
James A Fox
Karen L Valentino
Donald H Yamashiro
Original Assignee
Neurex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurex Corp filed Critical Neurex Corp
Application granted granted Critical
Publication of ATE140388T1 publication Critical patent/ATE140388T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AT91901056T 1989-11-22 1990-11-21 Zusammensetzungen enthaltend omega conotoxin peptide derivate und deren verwendung zur behandlung von ischämie-artigen neuronalen schädigungen ATE140388T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/440,094 US5051403A (en) 1989-11-22 1989-11-22 Method of treating ischemia-related neuronal damage

Publications (1)

Publication Number Publication Date
ATE140388T1 true ATE140388T1 (de) 1996-08-15

Family

ID=23747411

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91901056T ATE140388T1 (de) 1989-11-22 1990-11-21 Zusammensetzungen enthaltend omega conotoxin peptide derivate und deren verwendung zur behandlung von ischämie-artigen neuronalen schädigungen

Country Status (12)

Country Link
US (1) US5051403A (de)
EP (1) EP0593450B1 (de)
JP (1) JP3809184B2 (de)
AT (1) ATE140388T1 (de)
AU (1) AU648052B2 (de)
CA (1) CA2045473C (de)
DE (1) DE69027865T2 (de)
DK (1) DK0593450T3 (de)
ES (1) ES2091906T3 (de)
GR (1) GR3021087T3 (de)
HK (1) HK1006810A1 (de)
WO (1) WO1991007980A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653097B1 (en) 1991-08-15 2003-11-25 Merck & Co., Inc. Human calcium channel compositions and methods
US5851824A (en) * 1988-04-04 1998-12-22 Sibia Neurosciences, Inc. Human calcium channel α-1C/α-1D, α-2, β-1, and γsubunits and cells expressing the DNA
US5874236A (en) * 1988-04-04 1999-02-23 Sibia Neurosciences. Inc. DNA encoding human calcium channel α-1A, β1, β-2, and β-4 subunits, and assays using cells that express the subunits
US20040018510A1 (en) 1990-11-08 2004-01-29 Merck & Co., Inc. Human calcium channel compositions and methods
US6096514A (en) * 1988-04-04 2000-08-01 Sibia Neurosciences, Inc. Human calcium channel compositions and methods
US6387696B1 (en) 1988-04-04 2002-05-14 Merck & Co., Inc. Human calcium channel compositions and methods
US5846757A (en) * 1988-04-04 1998-12-08 Sibia Neurosciences, Inc. Human calcium channel α1, α2, and β subunits and assays using them
US5386025A (en) * 1990-02-20 1995-01-31 The Salk Institute Biotechnology/Industrial Associates Calcium channel compositions and methods
WO1989009834A1 (en) 1988-04-04 1989-10-19 The Salk Institute Biotechnology/Industrial Associ Calcium channel compositions and methods
US5407820A (en) * 1988-04-04 1995-04-18 The Salk Institute Biotechnology/Industrial Associates, Inc. Calcium channel α-2 subunit DNAs and cells expressing them
US5876958A (en) * 1988-04-04 1999-03-02 Sibia Neurosciences, Inc. Assays of cells expressing human calcium channels containing α1 β subunits
US5264371A (en) * 1989-11-22 1993-11-23 Neurex Corporation Screening method for neuroprotective compounds
US5559095A (en) * 1989-11-22 1996-09-24 Neurex Corporation Delayed treatment method of reducing ischemia-related neuronal damage
AU3074592A (en) * 1991-11-12 1993-06-15 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage
AU689438B2 (en) * 1991-12-30 1998-04-02 Azur Pharma International Limited Methods of producing analgesia and enhancing opiate analgesia
EP0556160A3 (de) * 1992-02-11 1993-10-27 Sandoz Ag Insektizide Toxine von Plectreurys tristis
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US5514774A (en) * 1993-06-29 1996-05-07 University Of Utah Research Foundation Conotoxin peptides
US5591821A (en) * 1993-07-16 1997-01-07 The University Of Utah Omega-conotoxin peptides
US6090623A (en) * 1993-08-11 2000-07-18 Merck & Co., Inc. Recombinant human calcium channel β4 subunits
US5739276A (en) * 1994-10-07 1998-04-14 University Of Utah Research Foundation Conotoxin peptides
US5670622A (en) * 1996-02-15 1997-09-23 University Of Utah Research Foundation Conotoxin peptide PIIIA
DK1336409T3 (da) * 1995-06-27 2007-08-13 Eisai R&D Man Co Ltd Sammensætninger af formuleringer til fremstilling af analgesimidler og til hæmning af fremadskridende neuropatiske smertelidelser
US6054429A (en) * 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
US5965534A (en) * 1995-11-22 1999-10-12 Alcon Laboratories, Inc. Use of ω-conotoxin analogs for treating retinal and optic nerve head damage
US5672682A (en) * 1996-03-18 1997-09-30 University Of Utah Research Foundation Conotoxin peptide PVIIA
US6528630B1 (en) 1997-12-03 2003-03-04 Merck & Co., Inc. Calcium channel compositions and methods
US6379882B1 (en) 1998-09-14 2002-04-30 Elan Pharmaceuticals, Inc. Method for selecting compounds for treating ischemia-related cellular damage
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
AU6415999A (en) * 1998-10-06 2000-04-26 Cognetix, Inc. Kappa-a conopeptides and uses therefor
WO2000021550A2 (en) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methods and compositions for treating neurodegenerative diseases
US6855805B2 (en) 1999-01-22 2005-02-15 University Of Utah Research Foundation α-conotoxin peptides
CA2361138A1 (en) 1999-01-22 2000-07-27 University Of Utah Research Foundation Alpha-conotoxin peptides
CA2379052A1 (en) * 1999-08-10 2001-02-15 Uab Research Foundation Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occurring conotoxins
AU2740401A (en) * 1999-12-30 2001-07-16 Cognetix, Inc. O-superfamily conotoxin peptides
EP1578787B1 (de) 2002-12-02 2012-11-14 Xenome Ltd Neue chi-conotoxinpeptide (-ii)
JP4565087B2 (ja) 2002-12-02 2010-10-20 ゼノム リミティッド 新規なχ−コノトキシン・ペプチド（−Ｉ）
US20090062211A1 (en) * 2003-03-05 2009-03-05 Florida Atlantic University Conopeptides and methods of use
US20060019892A1 (en) * 2003-03-05 2006-01-26 Florida Atlantic University Conopeptides and methods of use
EP1689401A1 (de) * 2003-10-02 2006-08-16 Elan Pharmaceuticals, Inc. Verfahren zur schmerzlinderung
ME01801B (me) * 2004-09-10 2011-02-28 Newron Pharm Spa UPOTREBA (R)-(HALOBENZILOKSI) BENZILAMINO-PROPANAMIDA KAO SELEKTIVNIH MODULATORA NATRIJUMOVIH l/ILI KALCIJUMOVIH KANALA
CN1304422C (zh) * 2005-09-15 2007-03-14 浙江大学 非酰胺化ω－芋螺毒素M ⅦA 及其制备方法和应用
DK1963280T3 (en) 2005-12-22 2015-12-14 Newron Pharm Spa 2-phenylethylamine derivatives by calcium and / or sodium channel
AU2008261325B2 (en) 2007-06-15 2012-12-06 Newron Pharmaceuticals S.P.A. Substituted 2- [2- (phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
WO2011032233A1 (en) 2009-09-21 2011-03-24 The University Of Queensland Novel omega conotoxin peptides
EP2723710B1 (de) 2011-06-27 2016-08-10 Newron Pharmaceuticals S.p.A. Fluorierte arylalkylaminocarboxamidderivate
CA2986704C (en) 2015-05-22 2022-03-01 Clemson University Research Foundation Conotoxin peptides for use in biofouling deterrence

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447356A (en) * 1981-04-17 1984-05-08 Olivera Baldomero M Conotoxins
US4925664A (en) * 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
US4950739A (en) * 1988-02-10 1990-08-21 New York University Membrane calcium channels and factors and methods for blocking, isolating and purifying calcium channels

Also Published As

Publication number Publication date
ES2091906T3 (es) 1996-11-16
DE69027865D1 (de) 1996-08-22
EP0593450A1 (de) 1994-04-27
CA2045473A1 (en) 1991-05-23
GR3021087T3 (en) 1996-12-31
US5051403A (en) 1991-09-24
CA2045473C (en) 2002-09-17
DE69027865T2 (de) 1997-01-02
AU6964091A (en) 1991-06-26
JPH05501715A (ja) 1993-04-02
EP0593450B1 (de) 1996-07-17
AU648052B2 (en) 1994-04-14
HK1006810A1 (en) 1999-03-19
WO1991007980A1 (en) 1991-06-13
DK0593450T3 (da) 1996-11-25
JP3809184B2 (ja) 2006-08-16

Similar Documents

Publication Publication Date Title
ATE140388T1 (de) Zusammensetzungen enthaltend omega conotoxin peptide derivate und deren verwendung zur behandlung von ischämie-artigen neuronalen schädigungen
ATE126441T1 (de) Pentigetide zur behandlung von nicht-ige- vermittelten entzündlichen erkrankungen.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATA162587A (de) Verfahren zur herstellung von neuen benzolderivaten sowie von diese derivate enthaltenden pharmazeutischen zusammensetzungen und verfahren zur verringerung von entzündung bei tieren
BG95935A (bg) Метод и средство за приемане на дексмедетомидин директно през кожата
DE3482754D1 (de) Medikament und medikamentoese zusammensetzung zur behandlung und/oder verhinderung von hautkrankheiten, verursacht durch eine entzuendung.
BG101118A (en) Therapeutical compounds
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
DE68910175D1 (de) Adsorbermodul sowie Adsorberapparat zur Behandlung von Vollblut.
DE58906239D1 (de) Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn.
DE2961609D1 (en) Sila-substituted 1,4-dihydropyridine derivatives, processes for their preparation, pharmaceutical compositions and process for their preparation
ES2044170T3 (es) Sal de estroncio, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen.
ES2089286T3 (es) Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos.
ES495459A0 (es) Procedimiento para la obtencion de nuevos carbamatos
DE59304087D1 (de) Placentaextrakt und Verfahren zu seiner Herstellung
IE870577L (en) Topical amide preparation
ATE69949T1 (de) Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
DK0538690T3 (da) Arylquinolyl-substituerede 1,4-dihydropyridin-dicarboxylsyrederivater, fremgangsmåde til deres fremstilling af deres anvendelse i lægemidler
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
MX9203208A (es) Composicion farmaceutica y metodo para el tratamiento de trastornos digestivos.
TR199801801T2 (xx) Madde k�t�ye kullan�m�n�n tedavisi.
ATE30238T1 (de) N-acylderivate von peptiden, ihre herstellung und verwendung bei der bekaempfung von krankheiten und mittel dafuer.
DE69420574D1 (de) Derivate von therapeutisch in der blutgerinnungskaskade wirksamen peptiden, verfahren zur herstellung und sie enthaltende pharmazeutische zubereitungen
DE69104058D1 (de) N-[(2-thenoylmerkapto-3-methyl)-butanoyl]-homocysteinthiolacton, verfahren zu seiner herstellung und diese enthaltende pharmaceutische zusammensetzungen.
ATE96039T1 (de) Arzneimittel und ihre verwendung zur behandlung von parasitosen.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee